ASCENDIS HEALTH LIMITED - Termination of the medical disposal, withdrawal and renewal of cautionary announcement

Termination of the medical disposal, withdrawal and renewal of cautionary announcement

 Ascendis Health Limited
 (Registration number 2008/005856/06)
 (Incorporated in the Republic of South Africa)
 Share code: ASC
 ISIN: ZAE000185005
 (“Ascendis Health” or “the Company”)


TERMINATION OF THE MEDICAL DISPOSAL, WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT IN RESPECT OF
THE MEDICAL DISPOSAL AND RENEWAL OF CAUTIONARY IN RESPECT OF THE AUSTELL PHARMA  TRANSACTION
                                     

Shareholders are referred to the announcement published on SENS on 1 February 2022, wherein shareholders
were, inter alia, advised that Ascendis Health SA Holdings Proprietary Limited (“AHSA”), a wholly owned
subsidiary of Ascendis Health, had concluded an agreement with Apex Management Services Proprietary Limited
(“Apex”), in terms of which AHSA would dispose of its entire interest in each of The Scientific Group Proprietary
Limited, Surgical Innovations Proprietary Limited (“SI”) and through the sale of SI, Ortho-Xact Proprietary Limited,
a subsidiary of SI, being the legal entities through which Ascendis Medical operates (the “Medical Disposal”).

Shareholders are advised that the Medical Disposal has been terminated by mutual agreement between the
parties.

WITHDRAWAL OF CAUTIONARY ANNOUNCEMENT IN RESPECT OF THE MEDICAL DISPOSAL

Following the termination of the Medical Disposal, AHSA will no longer be disposing of the majority of its assets
by way of a “series of transactions” for purposes of section 112(3)(b) of the Companies Act, 71 of 2008.
Accordingly, Shareholders are no longer required to exercise caution when dealing in Ascendis securities in
respect of the Medical Disposal.

RENEWAL OF CAUTIONARY ANNOUNCEMENT IN RESEPCT OF THE AUSTELL PHARMA TRANSACTION

Shareholders are referred to the cautionary announcement published on SENS on 16 May 2022 and the further
cautionary announcement published on SENS on 17 May 2022. Shareholders are advised to continue to exercise
caution when dealing in Ascendis securities until such time as there is clarity as to whether an agreement in
respect of the disposal of the Pharma business unit to Austell Pharmaceuticals Proprietary Limited may be
concluded.

RESPONSIBILITY STATEMENT

The board of directors of the Company (the “Board”) accepts responsibility for the information contained in this
announcement as it pertains to Ascendis Health. To the best of the Board's knowledge and belief, the information
contained in this announcement as it pertains to Ascendis Health is true and nothing has been omitted which is
likely to affect the importance of such information.


27 June 2022

Bryanston

Sponsor                                                                                                                1
Questco Corporate Advisory Proprietary Limited




                                                 2

Date: 27-06-2022 04:15:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.